Sugi Predict

Sugi Predict / Compounds / SCHEMBL1496411

SCHEMBL1496411

SCHEMBL1496411

CC(C)n1cnc2cnc(Cl)nc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 12/20 0.46
▸ CDK5 Q00535 11/20 0.46
▸ CDK5R1 Q15078 11/20 0.46
▸ CCNA2 P20248 10/20 0.46
▸ CCNA1 P78396 10/20 0.46
▸ DYRK1A Q13627 9/20 0.46
▸ CDK1 P06493 4/20 0.41
▸ CCNB1 P14635 3/20 0.40
▸ CCNE1 P24864 2/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ ADORA2A P29274 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ PI4KA P42356 1/20 0.38
▸ PI4K2B Q8TCG2 1/20 0.38
▸ PI4K2A Q9BTU6 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ HCAR3 P49019 1/20 0.33
▸ CCNB2 O95067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27538550 0.85 ADORA2A (0.44) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL4194084 0.81 CCNA2 (0.32) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL111660 0.81 KDM4E (0.36) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL15828265 0.80 CDK2 (0.41) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL6364047 0.79 CDK2 (0.56) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL27984740 0.79 CDK1 (0.43) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL28192314 0.79 CDK2 (0.40) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL17807736 0.79 CDK2 (0.40) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL21311451 0.79 CDK2 (0.40) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL28704049 0.77 FGFR1 (0.32) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118638119-B Pyrazole purine herbicide safener as well as preparation method and application thereof 东北农业大学 2025-02-28 — — CN disclosed
CN-118638119-A Pyrazole purine herbicide safener as well as preparation method and application thereof 东北农业大学 2024-09-13 — — CN disclosed
CN-117430609-B Purine derivative compound, preparation method and application thereof 东北农业大学 2024-05-24 — — CN disclosed
CN-117430609-A Purine derivative compound, preparation method and application thereof 东北农业大学 2024-01-23 — — CN disclosed
CN-110194769-A A kind of bis- target spot inhibitor of HDAC, CDK and the preparation method and application thereof 重庆医科大学 2019-09-03 — — CN disclosed
CN-109937039-A DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT 斯坦福国际研究院 2019-06-25 — — CN disclosed
CN-105916853-B 2,6- substituted purin derivatives and its purposes in treating proliferative diseases 辉瑞公司 2018-07-27 — — CN disclosed
CN-105037364-B The purine compound that pyrimidine as kinase inhibitor substitutes 维拉斯通股份有限公司 2018-04-27 — — CN disclosed
CN-107427521-A The inhibitor of cell cycle protein dependent kinase 达纳-法伯癌症研究所股份有限公司 2017-12-01 — — CN disclosed
CN-105001302-A Cyclic peptide inhibitors of hepatitis C virus replication INTERMUNE INC 2015-10-28 — — CN disclosed
CN-102203096-B Compounds that expand hematopoietic stem cells IRM LLC 2014-09-17 — — CN disclosed
US-20140135310-A1 SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES ADAMED SP. Z O.O. (PL) 2014-05-15 — — US disclosed
CN-102741270-A Cyclic peptide inhibitors of hepatitis c virus replication INTERMUNE INC 2012-10-17 — — CN disclosed
EP-2483290-A1 CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2012-08-08 — — EP disclosed
US-20110081315-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-04-07 — — US disclosed
US-20110081315-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-04-07 — — US disclosed
US-20110081315-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-04-07 — — US disclosed
WO-2011038293-A1 CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-03-31 — — WO disclosed
WO-2011038293-A1 CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-03-31 — — WO disclosed
CN-1231611-A Puring inhibitors of cylin dependent kinase 2 and I'kappa'beta-'alpha' CV THERAPEUTIC INC (US) 1999-10-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135310-A1 SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES DDC, INA, SCN5A CDK2 614/4885CDK5 296/4885CDK5R1 773/4885
US-20110081315-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, EIF4A2 CDK2 8/4885CDK5 242/4885CDK5R1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.